VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 438.7 USD | +0.29% |
|
+4.58% | +7.69% |
| 05-15 | Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director | CI |
| 05-14 | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 10.75B 14.64B | Sales 2025 * | 11.67B 15.89B | Capitalization | 113B 154B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.99B 5.43B | Net income 2025 * | 4.46B 6.08B | EV / Sales 2024 * | 9.2 x |
| Net cash position 2024 * | 13.97B 19.03B | Net cash position 2025 * | 19.01B 25.89B | EV / Sales 2025 * | 8.04 x |
| P/E ratio 2024 * |
28.8
x | P/E ratio 2025 * |
25.6
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | +0.28% | ||
| 1 week | +4.58% | ||
| Current month | +11.55% | ||
| 1 month | +11.17% | ||
| 3 months | +3.79% | ||
| 6 months | +27.75% | ||
| Current year | +7.69% |
1 week
417.50
439.26
1 month
391.01439.26
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
165.23448.40
10 years
63.68448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 438.2 | +0.16% | 431 771 |
| 24-05-15 | 437.5 | +2.08% | 1,059,443 |
| 24-05-14 | 428.6 | -0.31% | 935,891 |
| 24-05-13 | 429.9 | +1.69% | 939,753 |
| 24-05-10 | 422.8 | +0.90% | 1,064,604 |
Delayed Quote Nasdaq, May 16, 2024 at 12:38 pm
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
437.5
USD
Average target price
462.6
USD
Spread / Average Target
+5.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.69% | 113B | |
| +11.06% | 106B | |
| +0.41% | 22.27B | |
| -11.88% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -6.04% | 17.24B | |
| +6.89% | 14.29B | |
| +35.89% | 12.52B | |
| +288.55% | 8.6B |
- Stock Market
- Equities
- VRTX Stock